AI-generated analysis. Always verify with the original filing.
Theriva Biologics, Inc. filed a Form 8-K on March 12, 2026, under Item 2.02 disclosing results of operations via a press release attached as Exhibit 99.1. Item 9.01 lists the exhibits including the press release and Cover Page Interactive Data File (104).
Event Type
Disclosure
Mandatory
Variant
8-K
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securi
. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated March 12, 2026 104 Cov